Baseline characteristics of patients with COPD treated with Budesonide / Glycopyrronium / Formoterol in the real world; The RECORD Study

被引：0
|
作者：
Watz, Henrik [1 ]
Halbach, Marija [2 ]
Saathoff, Matthias [2 ]
Morris, Tamsin [3 ]
Watt, Michael
Singh, Dave [4 ,5 ]
机构：
[1] LungenClin Grosshansdorf, Pneumol Forschungsinst, Grosshansdorf, Germany
[2] AstraZeneca GmbH, AstraZeneca Deutschland, Hamburg, Germany
[3] AstraZeneca GmbH, Astrazeneca UK, London, England
[4] AstraZeneca GmbH, Astrazeneca UK, London, England
[5] Univ Manchester, Div Infect Immun Resp Med, Manchester, Lancs, England
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P11-02
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [31] COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
    Rabe, Klaus F.
    Martinez, Fernando J.
    Ferguson, Gary T.
    Singh, Dave
    Wedzicha, Jadwiga A.
    Jenkins, Martin
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    INTERNIST, 2021, 62 (SUPPL 2): : 181 - 181
  • [32] COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
    Rabe, K. F.
    Martinez, F. J.
    Ferguson, G. T.
    Singh, D.
    Wedzicha, J.
    Jenkins, M.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    PNEUMOLOGIE, 2021, 75 : S12 - S13
  • [33] Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD
    Worth, Heinrich
    Forster, Karin
    Eriksson, Goran
    Nihlen, Ulf
    Peterson, Stefan
    Magnussen, Helgo
    RESPIRATORY MEDICINE, 2010, 104 (10) : 1450 - 1459
  • [34] Budesonide/Formoterol Added to Tiotropium Improves the Management of COPD Patients.
    Welte, T.
    Miravitlles, M.
    Peterson, S.
    Polanowski, T.
    Kessler, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [35] Exacerbations and Real-world Outcomes (EROS) Among Patients With COPD Receiving Single Inhaler Triple Therapy of Budesonide/glycopyrrolate/formoterol Fumarate
    Pollack, M.
    Tkacz, J. P.
    Schinkel, J.
    Lewing, B.
    Agatep, B.
    Swisher, S.
    Patel, S.
    Edwards, D.
    Touchette, D.
    Portillo, E.
    Feigler, N.
    Strange, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [36] A new budesonide/formoterol inhalation therapy in patients with asthma, COPD and ACOS
    Tamasi, Lilla
    Galffy, Gabriella
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [37] Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts
    Shigeo Muro
    Hisatoshi Sugiura
    Patrick Darken
    Paul Dorinsky
    Respiratory Research, 22
  • [38] Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts
    Muro, Shigeo
    Sugiura, Hisatoshi
    Darken, Patrick
    Dorinsky, Paul
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [39] REAL-LIFE PERSISTENCE OF BUDESONIDE/FORMOTEROL SPIROMAX FOR THE MANAGEMENT OF ASTHMA AND COPD IN THE UK
    Benhaddi, H.
    Van der Tol, M.
    Price, D.
    Batsiou, M.
    Ariely, R.
    VALUE IN HEALTH, 2016, 19 (07) : A549 - A549
  • [40] Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation
    Ratoe Suraya
    Tatsuya Nagano
    Gusty Rizky Teguh Ryanto
    Wiwin Is Effendi
    Daisuke Hazama
    Naoko Katsurada
    Masatsugu Yamamoto
    Motoko Tachihara
    Noriaki Emoto
    Yoshihiro Nishimura
    Kazuyuki Kobayashi
    Respiratory Research, 23
12345